DENTALMONITORING
21.10.2021 11:24:09 CEST | Business Wire | Press release
DentalMonitoring has become the first dental software company to attain a valuation over $1 billion announcing a $150 million growth financing. The round is led by a new investment of $90 million from Mérieux Equity Partners and $60 million from Vitruvian Partners, an existing financial investor, demonstrating confidence in the company’s ambitious plans.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005463/en/
Since CEO and co-founder Philippe Salah launched the company in 2014, DentalMonitoring has become the first player to harness AI for remote monitoring in the dental and orthodontic fields. Driven by the treating doctor, DentalMonitoring’s AI automates messages and instructions sent to patients and practice staff to synchronize the delivery of care with the need of care. DentalMonitoring is also the first and only company offering virtual practice solutions for all dental professionals to help streamline and automate their workflow from initial virtual consultation, patient triage and conversion, to remote monitoring of all appliances and brands. To date, there are over one million patients in more than 50 countries that have taken more than a billion intraoral images on the DentalMonitoring platform.
“We are proud to be supported by leading international funds,” says DentalMonitoring CEO Philippe Salah. “This achievement marks a new milestone for the company, and is a testament to the new standard of care our team has brought to the profession. We will continue to deliver even more innovative solutions for dental professionals to help them provide better care and scale their practices.”
The company plans to use the proceeds to finance its rapid global growth, targeting an increased presence in the U.S. and expanding into new markets such as China and Japan. DentalMonitoring also plans to nearly double the number of employees in the next two years and target relevant acquisitions.
“AI is one of the major technologies to transform the delivery of healthcare and improve patient outcomes. DentalMonitoring’s team and their disruptive technology have convinced us of their ability to address the expanding demand for remote care capabilities for dental professionals. We are proud at Mérieux Equity Partner to back healthtech talent and look forward to supporting DentalMonitoring in their stellar growth, leveraging our international network.” added Caroline Folleas of Mérieux Equity Partners.
“By enabling remote dental care, DentalMonitoring is the biggest disruptor to the field since intraoral scanners in the 1990s and digital imaging in the 1980s. The company is an excellent fit with our investment strategy of backing best-in-class companies benefiting from strong market tailwinds with internationalization opportunities. Vitruvian renews its confidence to support the increasing needs of the company’s ambitious growth plans.” says Torsten Winkler of Vitruvian Partners.
Jefferies LLC, a global investment bank with a deep knowledge of the dental and software markets, served as Sole Placement Agent to DentalMonitoring on this investment round.
About DentalMonitoring
-
www.dental-monitoring.com
DentalMonitoring was started with a simple idea: oral care should be connected and continuous — even outside the practice. The company has created the world’s first virtual practice platform in dentistry, protected by over 200 patents, to address rapidly evolving patient expectations. Thanks to the largest database of dental images in the industry, DentalMonitoring has developed the most advanced and comprehensive doctor-driven AI solutions to help dental professionals provide superior care and a better patient experience. From patient lead engagement and conversion, providing treatment options through AI-generated reporting and advanced smile simulations, to remote monitoring of all types of treatments, DentalMonitoring’s unique platforms give dental professionals complete control over streamlined assessments and communication. DentalMonitoring has over 400 employees across 18 countries and 9 offices including Paris, Austin, London, Sydney and Hong Kong.
About Mérieux Equity Partners
- www.merieux-partners.com
Merieux Equity Partners ("MxEP") is an AMF-accredited management company dedicated to equity investments in the health and nutrition sector. With more than 45 companies backed, MxEP actively supports entrepreneurs and companies whose products and services bring differentiated and innovative solutions by providing privileged access to its expertise and the industrial, scientific and commercial network of Institut Mérieux (BioMerieux, Transgene, ABL, Mérieux Nutrisciences); MxEP currently manages over €1 billion in assets.
About Vitruvian Partners
- www.vitruvianpartners.com
Vitruvian is a leading international growth investor headquartered in London with offices in London, Stockholm, Munich, Luxembourg, San Francisco and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries. Vitruvian has backed over 100 companies and has assets under management of approximately €10 billion. Notable investments include global market leaders and disruptors in their field such as CRF Health, Fotona, Ada, doctari, Vestiaire Collective, Farfetch, Just Eat, Marqeta and TransferWise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005463/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom